Spero Therapeutics Inc [NASDAQ: SPRO] gained 17.37% or 0.37 points to close at $2.50 with a heavy trading volume of 24262867 shares.
The daily chart for SPRO points out that the company has recorded 117.39% gains over the past six months.
If we look at the average trading volume of 3.21M shares, SPRO reached to a volume of 24262867 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Spero Therapeutics Inc [SPRO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPRO shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPRO stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Spero Therapeutics Inc shares, keeping their opinion on the stock as In-line, with their previous recommendation back on December 20, 2024. While these analysts kept the previous recommendation, Evercore ISI raised their target price from $2 to $8. The new note on the price target was released on September 23, 2022, representing the official price target for Spero Therapeutics Inc stock. On January 22, 2021, analysts increased their price target for SPRO shares from 33 to 40.
The Average True Range (ATR) for Spero Therapeutics Inc is set at 0.22, with the Price to Sales ratio for SPRO stock in the period of the last 12 months amounting to 4.94. The Price to Book ratio for the last quarter was 4.13, with the Price to Cash per share for the same quarter was set at 0.87.
Trading performance analysis for SPRO stock
Spero Therapeutics Inc [SPRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 258.17. With this latest performance, SPRO shares gained by 279.94% in over the last four-week period, additionally plugging by 117.39% over the last 6 months – not to mention a rise of 73.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRO stock in for the last two-week period is set at 86.17, with the RSI for the last a single of trading hit 87.71, and the three-weeks RSI is set at 84.11 for Spero Therapeutics Inc [SPRO]. The present Moving Average for the last 50 days of trading for this stock 0.79, while it was recorded at 1.67 for the last single week of trading, and 1.02 for the last 200 days.
Spero Therapeutics Inc [SPRO]: A deeper dive into fundamental analysis
Spero Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.56 and a Current Ratio set at 2.56.
Spero Therapeutics Inc [SPRO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Spero Therapeutics Inc go to 7.97%.
An analysis of Institutional ownership at Spero Therapeutics Inc [SPRO]
The top three institutional holders of SPRO stocks are: ANSON FUNDS MANAGEMENT LP with ownership of 3.75 million shares, which is approximately 7.007%. VANGUARD GROUP INC, holding 1.77 million shares of the stock with an approximate value of $$2.3 million in SPRO stocks shares; and VANGUARD GROUP INC, currently with $$1.39 million in SPRO stock with ownership which is approximately 2.0026%.
